biote Corp. (NASDAQ:BTMD) Short Interest Up 22.6% in January

biote Corp. (NASDAQ:BTMD) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totaling 1,477,700 shares, an increase of 22.6% from the December 31st total of 1,205,571 shares. Based on an average daily volume of 206,954 shares, the short-interest ratio is presently 7.1 days. Approximately 4.3% of the shares of the stock are sold short. Approximately 4.3% of the shares of the stock are sold short. Based on an average daily volume of 206,954 shares, the short-interest ratio is presently 7.1 days.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. B. Riley reiterated a “neutral” rating on shares of biote in a report on Thursday, November 6th. Wall Street Zen cut shares of biote from a “buy” rating to a “hold” rating in a research note on Sunday, November 2nd. Weiss Ratings reiterated a “sell (d+)” rating on shares of biote in a research report on Monday, December 29th. Finally, Truist Financial set a $5.00 price target on shares of biote in a report on Wednesday, January 7th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $5.67.

biote Stock Performance

Shares of NASDAQ:BTMD opened at $2.14 on Wednesday. biote has a fifty-two week low of $2.03 and a fifty-two week high of $5.37. The company’s 50-day moving average is $2.51 and its 200 day moving average is $2.92. The company has a market capitalization of $97.71 million, a P/E ratio of 2.71 and a beta of 1.15.

biote (NASDAQ:BTMD) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.17. The firm had revenue of $47.96 million during the quarter, compared to the consensus estimate of $47.76 million. biote had a negative return on equity of 21.86% and a net margin of 14.72%. As a group, research analysts predict that biote will post 0.75 earnings per share for the current year.

Institutional Investors Weigh In On biote

Hedge funds have recently made changes to their positions in the company. Rice Hall James & Associates LLC lifted its holdings in shares of biote by 86.6% during the third quarter. Rice Hall James & Associates LLC now owns 227,024 shares of the company’s stock worth $681,000 after purchasing an additional 105,369 shares during the period. WINTON GROUP Ltd purchased a new stake in shares of biote during the third quarter worth approximately $309,000. Hillsdale Investment Management Inc. grew its stake in biote by 24.2% during the 2nd quarter. Hillsdale Investment Management Inc. now owns 420,273 shares of the company’s stock valued at $1,689,000 after acquiring an additional 81,829 shares in the last quarter. Bridgeway Capital Management LLC boosted its position in shares of biote by 142.1% during the 2nd quarter. Bridgeway Capital Management LLC now owns 121,053 shares of the company’s stock valued at $487,000 after acquiring an additional 71,053 shares during the last quarter. Finally, Strs Ohio lifted its holdings in biote by 50.9% in the fourth quarter. Strs Ohio now owns 166,300 shares of the company’s stock valued at $432,000 after acquiring an additional 56,100 shares during the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.